Pharmaceutical

FDA rejects Lykos MDMA therapy, asks for another Phase III trial

The company plans to ask the US FDA to reconsider its request for an additional Phase III trial for the approval of its MDMA capsules.

Aug 13, 2024 - 04:00
FDA rejects Lykos MDMA therapy, asks for another Phase III trial
The company plans to ask the US FDA to reconsider its request for an additional Phase III trial for the approval of its MDMA capsules.
Read the original article

Tags:

Previous Article

Leap Consulting launches practice to assist labs with FDA’s LDT ruling

Next Article

FDA approves IASO Bio’s IND for equecabtagene autoleucel

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

The fight for control of methadone, addiction treatment’s ‘miracle molecule’

The fight for control of methadone, addiction treatment...

Oct 20, 2023

These are the need-to-know biotech stories from this weekend

These are the need-to-know biotech stories from this we...

Nov 13, 2023

Sandoz targets barriers to biosimilar accessibility with latest initiative

Sandoz targets barriers to biosimilar accessibility wit...

Jun 15, 2023